Alex A. Adjei - Concepedia

Author

Alex A. Adjei

Mayo Clinic ORCID

Also Known As

A A Adjei, A A. Adjei, A ADJEI, A Adjei, A. A. Adjei, A. Adjei, A., Adjei, A.A Adjei, A.A. Adjei, Adjei, A.A.

779

Publications

37.8K

Citations

H-Index

164

Concepts

All Affiliations

Mayo Clinic Roswell Park Comprehensive Cancer Center Mayo Clinic in Arizona Mayo Clinic in Florida WinnMed

About

Alex A. Adjei is an author at Mayo Clinic specializing in medicine, oncology, and radiation oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	47	126	12.2K
2	Health Sciences	21	32	5.4K
3	Public Health	7	7	1.2K
4	Natural Sciences	5	5	413
5	Nursing	1	1	79

Alex A. Adjei

235

Publications

22K

Citations

H-Index

Page 1

	Year	Citations
Non-Small Cell Lung Cancer: Epidemiology, Risk Factors, Treatment, and Survivorship Julian R. Molina, Ping Yang, Stephen D. Cassivi, Mayo Clinic Proceedings Cancer EpidemiologyAdvanced Lung DiseaseMedicineCancer ManagementPathology	2008	2.8K
Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up Solange Peters, Alex A. Adjei, Cesare Gridelli, Annals of Oncology Advanced Lung DiseaseMedicineCancer ManagementOncologyRadiation Oncology	2012	927
Control of Confounding and Reporting of Results in Causal Inference Studies. Guidance for Authors from Editors of Respiratory, Sleep, and Critical Care Journals David J. Lederer, Scott C. Bell, Richard D. Branson, Annals of the American Thoracic Society Quasi-experimentCausal InferenceCritical Care MedicineBiasClinical Epidemiology	2018	697
Multicenter Phase II Study of the Oral MEK Inhibitor, CI-1040, in Patients With Advanced Non-Small-Cell Lung, Breast, Colon, and Pancreatic Cancer John J. Rinehart, Alex A. Adjei, Patricia LoRusso, Journal of Clinical Oncology	2004	635
Phase I Pharmacokinetic and Pharmacodynamic Study of the Oral, Small-Molecule Mitogen-Activated Protein Kinase Kinase 1/2 Inhibitor AZD6244 (ARRY-142886) in Patients With Advanced Cancers Alex A. Adjei, Roger B. Cohen, Wilbur A. Franklin, Journal of Clinical Oncology	2008	572
2nd ESMO Consensus Conference on Lung Cancer: early-stage non-small-cell lung cancer consensus on diagnosis, treatment and follow-up Johan Vansteenkiste, Lucio Crinò, Christophe Dooms, Annals of Oncology Advanced Lung DiseaseMedicineCancer ManagementEsmo Consensus ConferencePulmonary Blastoma	2014	492
A Phase I dose-escalation study of sibrotuzumab in patients with advanced or metastatic fibroblast activation protein-positive cancer. Andrew M. Scott, G. Wiseman, Sydney Welt, PubMed	2003	441
Clinical Features of 5,628 Primary Lung Cancer Patients Ping Yang, Mark S. Allen, Marie Christine Aubry, CHEST Journal MedicinePathologyClinical FeaturesPulmonary BlastomaOncology	2005	398
Phase I and Pharmacodynamic Study of the Oral MEK Inhibitor CI-1040 in Patients With Advanced Malignancies Patricia LoRusso, Alex A. Adjei, Mary Varterasian, Journal of Clinical Oncology	2005	397
Advances in Targeting the Ras/Raf/MEK/Erk Mitogen-Activated Protein Kinase Cascade with MEK Inhibitors for Cancer Therapy Bret B. Friday, Alex A. Adjei Clinical Cancer Research	2008	379

Page 1